A detailed history of State Street Corp transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, State Street Corp holds 3,204,718 shares of XERS stock, worth $9.81 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,204,718
Previous 3,258,633 1.65%
Holding current value
$9.81 Million
Previous $7.33 Million 24.58%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.06 - $2.96 $111,064 - $159,588
-53,915 Reduced 1.65%
3,204,718 $9.13 Million
Q2 2024

Aug 14, 2024

BUY
$1.7 - $2.45 $74,148 - $106,861
43,617 Added 1.36%
3,258,633 $7.33 Million
Q1 2024

May 15, 2024

BUY
$2.04 - $3.22 $1 Million - $1.58 Million
490,890 Added 18.02%
3,215,016 $7.11 Million
Q4 2023

Feb 14, 2024

BUY
$1.47 - $2.36 $226,385 - $363,449
154,004 Added 5.99%
2,724,126 $6.4 Million
Q3 2023

Nov 14, 2023

BUY
$1.8 - $2.69 $45,403 - $67,852
25,224 Added 0.99%
2,570,122 $4.78 Million
Q2 2023

Aug 14, 2023

BUY
$1.82 - $2.98 $475,615 - $778,754
261,327 Added 11.44%
2,544,898 $6.67 Million
Q1 2023

May 15, 2023

BUY
$1.03 - $1.63 $142,491 - $225,495
138,341 Added 6.45%
2,283,571 $3.72 Million
Q4 2022

Feb 14, 2023

SELL
$1.14 - $1.65 $33,074 - $47,871
-29,013 Reduced 1.33%
2,145,230 $2.85 Million
Q3 2022

Nov 15, 2022

BUY
$1.37 - $1.93 $73,305 - $103,270
53,508 Added 2.52%
2,174,243 $3.39 Million
Q2 2022

Aug 15, 2022

BUY
$1.48 - $2.64 $2.57 Million - $4.58 Million
1,735,974 Added 451.18%
2,120,735 $3.27 Million
Q1 2022

May 16, 2022

BUY
$2.0 - $2.87 $36,504 - $52,383
18,252 Added 4.98%
384,761 $985,000
Q4 2021

Feb 14, 2022

BUY
$1.8 - $2.93 $659,716 - $1.07 Million
366,509 New
366,509 $1.07 Million

Others Institutions Holding XERS

About Xeris Biopharma Holdings, Inc.


  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $416M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.